0
0
Primary Healthtech Private Limited, a company founded by alumni of the Indian Institute of Technology Guwahati (IITG), has developed an indigenous point-of-care testing device. This innovative device is designed to assess 25 parameters in the blood, allowing for early detection of chronic diseases related to kidney, liver, heart, and pancreas functions.
The MobilabTM device, as stated by CEO Sahil Jagnani, is capable of conducting 150 tests on a single charge and is operated through an IoT-enabled Android app. Its versatility enables usage in even the most remote areas of the country. According to a recent report from the World Health Organization (WHO), non-communicable diseases (NCDs) account for nearly 74 percent (approximately 41 million) of global deaths.
The mission of MobilabTM, according to its founder, is to expedite early detection, facilitate disease management, and offer cost-effective diagnosis to the public. Jagnani emphasized that the device aligns with the government’s ‘Make in India’ initiative and is expected to contribute to reducing dependence on imports.
He asserted that MobilabTM will make testing accessible at the patient’s location, enabling both early detection and effective long-term disease management. Currently, eleven parameters, including cholesterol levels, LDL, HDL, and triglycerides for heart health, total bilirubin, albumin, and total protein for liver function, creatinine, glucose, and uric acid for kidney function, as well as hemoglobin and glucose for haematology, have been validated in NABL accredited and government labs.
The device generates data, a digital report, and an electronic health record for the patient within ten minutes, which can be readily shared with healthcare professionals.
